Vistin Pharma ASALTS:0RAM 77 Earnings Yield (Joel Greenblatt) % is 11.35% as of Mar. 2026, which is 80% above its 10-year median of 6.31. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.63 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,013 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 86.87% on this metric.
Vistin Pharma ASA's Enterprise Value for the quarter that ended in Mar. 2026 was kr947.1 Mil.
Vistin Pharma ASA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was kr107.5 Mil. Vistin Pharma ASA's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 11.35%.
The historical rank and industry rank for Vistin Pharma ASA's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
LTS:0RAM'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -991.93 Med: 6.31 Max: 1082.69
Current: 11.97
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Vistin Pharma ASA was 1082.69%. The lowest was -991.93%. And the median was 6.31%.
LTS:0RAM's Earnings Yield (Joel Greenblatt) % is ranked better than 86.87% of 1013
companies
in the Drug Manufacturers industry
Industry Median: 3.23
vs LTS:0RAM: 11.97
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Vistin Pharma ASA's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Vistin Pharma ASA Earnings Yield (Joel Greenblatt) % Related Terms
Vistin Pharma ASA Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Vistin Pharma ASAs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Vistin Pharma ASA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr107.5 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 11.35% mean?
Vistin Pharma ASA (LTS:0RAM) has a Earnings Yield (Joel Greenblatt) % of 11.35% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Vistin Pharma ASA and its competitors. This is 80% above median its historical median of 6.31. According to the industry distribution chart, Vistin Pharma ASA ranks #133 out of 1013 companies in the Drug Manufacturers industry, placing it in the top 13.1%.
Is Vistin Pharma ASA's Earnings Yield (Joel Greenblatt) % too high?
Vistin Pharma ASA's current Earnings Yield (Joel Greenblatt) % of 11.35% is 80% above median its 10-year median of 6.31. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.23. Vistin Pharma ASA's value of 11.35% is 251.4% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #133 out of 1013 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #133 out of 1013 companies for Earnings Yield (Joel Greenblatt) %. This places Vistin Pharma ASA in the top 13% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.23. Vistin Pharma ASA's value of 11.35% is 251.4% above this benchmark. While the company's 10-year median is 6.31 vs. the industry median of 3.23, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.23, based on 1,013 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Earnings Yield (Joel Greenblatt) % of 11.35% is 251.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Earnings Yield (Joel Greenblatt) % is 11.35%, which is 80% above median its own 10-year median of 6.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.63, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 11.35%, which is 80% above median its 10-year median of 6.31 and 251.4% above the Drug Manufacturers industry median of 3.23. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Earnings Yield (Joel Greenblatt) % is 11.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.63.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Earnings Yield (Joel Greenblatt) %: 11.35% (80% above median its 10-year median of 6.31)
GF Value™: kr25.63 vs. price of kr20.70 (19.2% below fair value)
Industry Position: 251.4% above the Drug Manufacturers median (#133 of 1013)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
